Retrospective Study
Copyright ©The Author(s) 2015.
World J Gastroenterol. Sep 7, 2015; 21(33): 9765-9773
Published online Sep 7, 2015. doi: 10.3748/wjg.v21.i33.9765
Table 1 Demographic characteristics of the enrolled population at baseline
n = 139
Gender (%, male/female)50.4/49.6
Age (yr)146.8 ± 14.0
HCV RNA (log10, IU/mL)26.3 (3.0, 7.74)
ALT (IU/L)260.0 (10, 527)
AST (IU/L)246.0 (16.0, 264)
TBIL (μmol/L)216.1 (5.0, 150)
DBIL (μmol/L)24.51 (0.48, 108)
ALB (g/L)142.57 ± 4.16
Positive antibodies (%, TPOAb/TGAb)15.8%/8.6%
Table 2 Summary of thyroid dysfunction induced by pegylated interferon-α2a and ribavirin
No.GenderAge(yr)Diagnosis timeFT3FT4TSHDiagnosisOutcome
(3.50-6.50 pmol/L)(11.48-22.70 pmol/L)(0.35-5.50 μIU/mL)
1Female5312th wk4.8111.666.62Sub hypoNormal
2Female6148th wk4.6712.1919.61Sub hypoNormal
3Female4224th wk6.0211.567.13Sub hypoNormal
4Female4024th wk5.8811.718.95Sub hypoNormal
5Female4624th wk4.1314.136.25Sub hypoNormal
6Female5624th wk5.4624.5511.01Sub hypoNormal
7Female5648th wk5.1212.898.45Sub hypoNormal
8Female4448th wk4.0024.366.31Sub hypoNormal
9Female4112th wk6.1913.485.58Sub hypoSub hyper
10Female4512th wk5.2719.246.15Sub hypoNormal
11Male3924th wk5.3613.4523.19Sub hypoNormal
12Male2824th wk5.4415.276.66Sub hypoNormal
13Male5324th wk3.7914.678.71Sub hypoNormal
14Male5012th wk6.2011.8537.42Sub hypoNormal
15Male5124th wk5.1512.476.46Sub hypoNormal
16Male1824th wk4.9513.996.16Sub hypoNormal
17Female4324th wk6.3413.890.32Sub hyperSub hyper
18Female2136th wk4.3721.240.29Sub hyperNormal
19Female3836th wk5.7212.970.24Sub hyperNormal
20Female2824th wk4.1921.240.32Sub hyperNormal
21Female4224th wk4.6716.470.01Sub hyperNormal
22Female3324th wk5.3111.580.12Sub hyperNormal
23Male7024th wk5.7716.700.02Sub hyperNormal
24Female2124th wk5.905.976.16HypoTherapy
25Female6648th wk6.030.976.58HypoTherapy
Table 3 Baseline characteristics of the thyroid dysfunction vs non-thyroid dysfunction chronic hepatitis C patients
TDIFNNTDIFNP value
Gender (%, male/female)28.0/72.055.3/45.70.014
Age (yr)143.40 ± 13.6047.50 ± 14.00.183
HCV RNA (log10, IU/mL)26.23 (3.54, 7.52)6.36 (3.0, 7.74)0.919
ALT (IU/L)281.0 (26, 416)55.0 (10, 527)0.162
AST (IU/L)267.0 (26, 248)41.5 (16, 264)0.018
TBIL(μmol/L)217.20 (8.9, 36.4)16.0 (5.0, 150.0)0.732
DBIL(μmol/L)24.57 (0.69, 13.80)4.5 (0.48, 108)0.447
ALB (g/L)142.30 ± 4.2442.62 ± 4.150.764
TPOAb positivity24.2%12.3%0.047
TGAb positivity12.0%7.9%0.469
CXCL10 level (pg/mL)1310.0 ± 163.4495.20 ± 244.20.012
Table 4 Numbers of patients treated with combination therapy positive for thyroid autoantibodies at enrollment and at the end of treatment
TPOAb (+) onlyTGAb (+) onlyBoth (+)Both (-)
At baseline1275115
At the end of treatment13108108